Fruquintinib With PD-1 Inhibitors Versus TAS-102 With Bevacizumab in Late-Line mCRC
Condition: Metastatic Colorectal Adenocarcinoma Interventions: Drug: Fruquintinib; Drug: PD-1 inhibitors; Drug: Trifluridine/Tipiracil; Drug: Bevacizumab Sponsor: Hunan Cancer Hospital Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials